Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

10 June 2021

Small companies bear large burden of developing superbug treatments – report

Kristen Hallam for S&P Global Market Intelligence writes about the newest report from the Access to Medicine Foundation's Antimicrobial Resistance Benchmark.

Hallam delves into the Foundation's latest research, which looks at the small drug-makers that are responsible for 75% of the world's late-stage R&D antimicrobial projects. Despite their crucial role in the world of medicine, these small companies are often under-funded and risk bankruptcy, leaving promising medicines unable to reach patients who need them. 

Fatema Rafiqi, Research Programme Manager for the Antimicrobial Resistance (AMR) Benchmark, is quoted in the article. Fatima compares the response to the COVID-19 pandemic to the serious threat of a future AMR-fueled pandemic. Fatema explains, "the rally around COVID was so much different and we need to push for that kind of rally" for new antimicrobials.

Click to read the full article.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved